BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D.

波士顿，2024年3月4日/PRNewswire/--Elevation Oncology，Inc.（纳斯达克：ELEV），一家创新的肿瘤学公司，专注于发现和开发选择性癌症疗法，以治疗一系列严重未满足医疗需求的实体瘤患者，今天宣布任命Julie Cherrington博士。

and Alan Sandler, M.D., to its Board of Directors..

和医学博士艾伦·桑德勒（AlanSandler）加入董事会。。

'We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors,' said Steve Elms, Chairman of Elevation Oncology. 'Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board, I look forward to Julie and Alan's many insights into both clinical and regulatory strategy as Elevation Oncology continues to advance its pipeline of differentiated, potentially best-in-class antibody-drug conjugate (ADC) therapies.'.

Elevation Oncology董事长史蒂夫·埃尔姆斯（SteveElms）说：“我们很高兴欢迎朱莉（Julie）和艾伦（Alan）成为Elevation Oncology的最新董事。”两者都是经验丰富的药物开发人员，他们为癌症治疗的多种靶向疗法的进步和批准做出了贡献。我代表董事会期待Julie和Alan对临床和监管策略的深入了解，因为Elevation Oncology继续推进其分化的，可能是同类最佳的抗体-药物偶联物（ADC）疗法。”。

'I am excited to lend my expertise in drug development and company building to help Elevation Oncology advance selective cancer therapies to improve the care and treatment of patients with solid tumors,' said Dr. Cherrington. 'With an initial update from its ongoing Phase 1 clinical trial of EO-3021 on-track for mid-year and the nomination of a HER3-ADC development candidate expected before year-end, Elevation Oncology is on the precipice of a significant transformation, and I look forward to partnering with management to thoughtfully move both programs into later stages of clinical and preclinical development, respectively.'.

Cherrington博士说：“我很高兴能够利用我在药物开发和公司建设方面的专业知识，帮助Elevation Oncology推进选择性癌症治疗，以改善实体瘤患者的护理和治疗。”。“随着正在进行的EO-3021第一阶段临床试验的初步更新有望在年中进行，预计年底前将提名一名HER3-ADC开发候选人，高地肿瘤学即将发生重大转变，我期待着与管理层合作，深思熟虑地将这两个项目推进临床和临床前开发的后期阶段，分别。”。

'Now is an exciting time to join Elevation Oncology,' said Dr. Sandler. 'In recent months, the company has focused its efforts on developing a pipeline of differentiated ADCs to address well-validated cancer targets that could potentially provide better safety and efficacy to patients living with solid tumors.

桑德勒博士说：“现在是加入高程肿瘤学的激动人心的时刻。”近几个月来，该公司专注于开发一系列分化的ADC，以解决经过充分验证的癌症靶点，这些靶点可能为实体瘤患者提供更好的安全性和有效性。

I am eager to work closely with the team and to apply our collective expertise in ADC and oncology drug discovery and development to bring these novel medicines to patients with unmet needs.'.

我渴望与团队密切合作，并将我们在ADC和肿瘤药物发现和开发方面的集体专业知识应用于将这些新药带给未满足需求的患者。”。

Dr. Cherrington is an experienced life science executive with extensive insight in bringing novel product candidates into the clinic and through to commercialization. Over the course of her career, Dr. Cherrington contributed to the successful development of multiple U.S. Food and Drug Administration-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®, and served as President and Chief Executive Officer (CEO) for several biotechnology companies.

Cherrington博士是一位经验丰富的生命科学高管，在将新型候选产品引入临床并实现商业化方面具有广泛的洞察力。在她的职业生涯中，Cherrington博士为多个美国食品和药物管理局批准的产品的成功开发做出了贡献，包括SUTENT®、PALLADIA®、VISTIDE®、VIREAD®和HEPSERA®，并担任多家生物技术公司的总裁兼首席执行官（CEO）。

She currently serves as a Venture Partner at Brandon Capital Partners, as well as Chair of Actym Therapeutics, Chair of Tolremo Therapeutics, and director at Syncona Limited, Sardona Therapeutics, KisoJi Biotechnology and MycRx. Earlier, Dr. Cherrington served as CEO of QUE Oncology, and as President and CEO of Arch Oncology, Revitope Oncology, Inc., Zenith Epigenetics, and Pathway Therapeutics.

她目前担任Brandon Capital Partners的风险合伙人，以及Actym Therapeutics主席、Tollemo Therapeutics主席，Syncona Limited、Sardona Therapeutics、KisoJi Biotechnology和MycRx董事。早些时候，Cherrington博士曾担任QUE Oncology的首席执行官，以及Arch Oncology，Revitope Oncology，Inc.，Zenith Epigenetics和Pathway Therapeutics的总裁兼首席执行官。

Dr. Cherrington holds a B.S. in Biology and an M.S. in Microbiology from the University of California, Davis, and completed her Ph.D. training in Microbiology and Immunology at the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco..

Cherrington博士拥有加利福尼亚大学戴维斯分校的生物学学士学位和微生物学硕士学位，并在明尼苏达大学和斯坦福大学完成了微生物学和免疫学博士学位培训。她在加州大学旧金山分校获得博士后奖学金。。

Dr. Sandler is an accomplished leader in oncology and drug development, with experience leading clinical development and operations, regulatory affairs, drug safety and asset development strategy across industry and academia. He currently serves as Executive Vice President and Chief Medical Officer of Mirati Therapeutics, a Bristol Myers Squibb Company.

桑德勒博士是肿瘤学和药物开发领域的杰出领导者，拥有领导临床开发和运营、监管事务、药物安全和跨行业和学术界的资产开发战略的经验。他目前担任百时美施贵宝公司Mirati Therapeutics的执行副总裁兼首席医疗官。

Prior to joining Mirati Therapeutics, Dr. Sandler was President and Global Head of Oncology for Zai Lab, where he led global oncology development for the company. Previously, Dr. Sandler was the Senior Vice President and Global Head, Product Development of Oncology Solid Tumors at Genentech, a member of the Roche Group.

在加入Mirati Therapeutics之前，桑德勒博士是Zai Lab的总裁兼肿瘤学全球负责人，他在那里领导了该公司的全球肿瘤学开发。此前，桑德勒博士曾任罗氏集团成员基因泰克公司肿瘤实体瘤产品开发高级副总裁兼全球负责人。

He has also held academic roles at Oregon Health and Science University, Indiana University and Vanderbilt University. Dr. Sandler holds an M.D. from Rush Medical College and completed his training in internal medicine and a fellowship in medical oncology at Yale-New Haven Medical Center. He has published over 300 publications including peer-reviewed articles, reviews, abstracts and book chapters..

他还曾在俄勒冈健康与科学大学、印第安纳大学和范德比尔特大学担任学术职务。桑德勒博士拥有拉什医学院的医学博士学位，并在耶鲁纽黑文医学中心完成了内科培训和肿瘤学研究金。他出版了300多种出版物，包括同行评议的文章、评论、摘要和书籍章节。。

About Elevation Oncology, Inc.

关于Elevation Oncology，Inc。

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient's unique tumor characteristics.

Elevation Oncology是一家创新的肿瘤学公司，专注于发现和开发选择性癌症疗法，以治疗一系列实体瘤患者，这些患者的医疗需求尚未得到满足。我们正在重新考虑药物开发，寻找创新的选择性癌症治疗方法，可以与患者独特的肿瘤特征相匹配。

Our lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated oncology target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are evaluating EO-3021 in a Phase 1 study in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers.

我们的主要候选药物EO-3021是一种潜在的同类最佳抗体-药物偶联物（ADC），旨在靶向Claudin 18.2，这是一种临床验证的肿瘤学靶标。EO-3021选择性地将细胞毒性有效载荷直接递送至表达Claudin 18.2的癌细胞。我们正在一项1期研究中评估EO-3021，该研究针对可能表达Claudin 18.2的晚期，不可切除或转移性实体瘤患者，包括胃癌，胃食管癌，胰腺癌或食管癌。

We are also exploring other opportunities through new or existing partnerships and business development opportunities to expand our oncology pipeline. For more information, visit www.ElevationOncology.com..

我们还通过新的或现有的合作伙伴关系和业务发展机会探索其他机会，以扩大我们的肿瘤学渠道。有关更多信息，请访问www.ElevationOncology.com。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical and preclinical development activities, expected timing of announcements of clinical results and trial details, potential benefits of Elevation Oncology's product candidates, potential market opportunities for Elevation Oncology's product candidates and the ability of Elevation Oncology's product candidates to treat their targeted indications.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款含义内的前瞻性声明，包括但不限于预期的临床和临床前开发活动，临床结果和试验细节的预期公布时间，Elevation Oncology候选产品的潜在益处，Elevation Oncology候选产品的潜在市场机会以及Elevation Oncology候选产品治疗其目标适应症的能力。

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'will,' 'would,' and other words and terms of similar meaning.

除历史事实陈述外的所有陈述均为可被视为前瞻性陈述的陈述。这些前瞻性陈述可能伴随着诸如“目标”、“预期”、“相信”、“可能”、“估计”、“预期”、“预测”、“目标”、“打算”、“可能”、“可能”、“计划”、“可能”、“潜力”、“意志”、“将会”等类似含义的词语和术语。

Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain.

虽然Elevation Oncology认为这些前瞻性陈述中反映的期望是合理的，但Elevation Oncology不能保证未来的事件，结果，行动，活动水平，表现或成就，生物技术开发的时间和结果以及潜在的监管批准本质上是不确定的。

Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory des.

前瞻性声明具有可能导致Elevation Oncology的实际活动或结果与任何前瞻性声明中所表达的显着不同的风险和不确定性，包括与Elevation Oncology推进其候选产品的能力，临床前研究和临床试验的时间和结果相关的风险和不确定性，候选产品的批准和商业化，潜在监管des的接收和时间安排。

Elevation Oncology Investor and Media Contact

Elevation肿瘤学投资者和媒体联系

Candice Masse, 978-879-7273Senior Director, Corporate Communications & Investor Relationscmasse@elevationoncology.com

Candice Masse，978-879-7273企业传播与投资者高级董事Relationscmasse@elevationoncology.com

SOURCE Elevation Oncology

源抬高肿瘤学